120 related articles for article (PubMed ID: 32229544)
1. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir.
Su F; Berry K; Ioannou GN
Gut; 2021 Feb; 70(2):370-378. PubMed ID: 32229544
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece.
Sinakos E; Kachru N; Tsoulas C; Jeyakumar S; Smith NJ; Yehoshua A; Cholongitas E
J Comp Eff Res; 2024 Apr; 13(4):e230090. PubMed ID: 38317634
[No Abstract] [Full Text] [Related]
3. The Risk of Hepatocellular Carcinoma in Entecavir Versus Tenofovir Treated US Cohort With Chronic Hepatitis B Virus.
Kramer JR; Richardson PA; Kim H; Hsu YC; Kanwal F; El-Serag HB
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1111-1113.e3. PubMed ID: 35276326
[TBL] [Abstract][Full Text] [Related]
4. A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B.
Lee HW; Kim H; Park T; Park SY; Chon YE; Seo YS; Lee JS; Park JY; Kim DY; Ahn SH; Kim BK; Kim SU
Liver Int; 2023 Aug; 43(8):1813-1821. PubMed ID: 37452503
[TBL] [Abstract][Full Text] [Related]
5. Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study.
Jang TY; Liang PC; Jun DW; Jung JH; Toyoda H; Wang CW; Yuen MF; Cheung KS; Yasuda S; Kim SE; Yoon EL; An J; Enomoto M; Kozuka R; Chuma M; Nozaki A; Ishikawa T; Watanabe T; Atsukawa M; Arai T; Hayama K; Ishigami M; Cho YK; Ogawa E; Kim HS; Shim JJ; Uojima H; Jeong SW; Ahn SB; Takaguchi K; Senoh T; Buti M; Vargas-Accarino I E; Abe H; Takahashi H; Inoue K; Yeh ML; Dai CY; Huang JF; Huang CF; Chuang WL; Nguyen MH; Yu ML
J Gastroenterol Hepatol; 2024 Mar; ():. PubMed ID: 38480009
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study.
Ndow G; Vo-Quang E; Shimakawa Y; Ceesay A; Tamba S; Njai HF; Bojang L; Hateley C; Takao Y; Opoku E; Warsop Z; Ingiliz P; D'Alessandro U; Chemin I; Mendy M; Thursz M; Njie R; Lemoine M
Lancet Glob Health; 2023 Sep; 11(9):e1383-e1392. PubMed ID: 37517420
[TBL] [Abstract][Full Text] [Related]
7. TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.
Zhao J; Zhou L; Zhang Y; Cheng J; Zeng Y; Li X
Sci Rep; 2024 Apr; 14(1):8161. PubMed ID: 38589540
[TBL] [Abstract][Full Text] [Related]
8. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B.
Kim TH; Kim JH; Yim HJ; Seo YS; Yim SY; Lee YS; Jung YK; Yeon JE; Um SH; Byun KS
Gut Liver; 2024 Mar; 18(2):305-315. PubMed ID: 38213189
[TBL] [Abstract][Full Text] [Related]
9. Analysis of primary care electronic health record data of people living with hepatitis B virus: infection and hepatocellular carcinoma risk associated with socio-economic deprivation.
Campbell C; Wang T; Gillespie I; Barnes E; Matthews PC
Public Health; 2024 Jan; 226():215-227. PubMed ID: 38091810
[TBL] [Abstract][Full Text] [Related]
10. Extrahepatic Malignancies and Antiviral Drugs for Chronic Hepatitis B: A Nationwide Cohort Study.
Hur MH; Lee DH; Lee JH; Kim MS; Park J; Shin H; Chung SW; Cho HJ; Park MK; Jang H; Lee YB; Yu SJ; Lee SH; Jung YJ; Kim YJ; Yoon JH
Clin Mol Hepatol; 2024 May; ():. PubMed ID: 38726505
[TBL] [Abstract][Full Text] [Related]
11. Which risk model can better predict hepatocellular carcinoma in hepatitis B patients with an antiviral treatment duration of over 1 year?
Guan MC; Ding Q; Zhu H
J Hepatol; 2024 Apr; 80(4):e160. PubMed ID: 37414258
[No Abstract] [Full Text] [Related]
12. Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report.
Kakiuchi T; Takahashi H; Iwane S; Koji A; Matsuo M
Clin Case Rep; 2021 Mar; 9(3):1752-1758. PubMed ID: 33768929
[TBL] [Abstract][Full Text] [Related]
13. Enhancing the understanding of the risk of incident fracture in entecavir- and TDF-treated elderly patients with chronic hepatitis B (CHB).
Wen Z
J Hepatol; 2024 May; ():. PubMed ID: 38762168
[No Abstract] [Full Text] [Related]
14. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis.
Choi WM; Choi J; Lim YS
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):246-258.e9. PubMed ID: 32407970
[TBL] [Abstract][Full Text] [Related]
15. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis.
Tseng CH; Hsu YC; Chen TH; Ji F; Chen IS; Tsai YN; Hai H; Thuy LTT; Hosaka T; Sezaki H; Borghi JA; Cheung R; Enomoto M; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1039-1052. PubMed ID: 33007228
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis.
Dave S; Park S; Murad MH; Barnard A; Prokop L; Adams LA; Singh S; Loomba R
Hepatology; 2021 Jan; 73(1):68-78. PubMed ID: 32277491
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the long-term efficacy between tenofovir and entecavir in chronic hepatitis B patients.
Liu K; Peng P; Cai F; Huang J
Gut; 2020 Sep; ():. PubMed ID: 32928915
[No Abstract] [Full Text] [Related]
19. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Wen Z; Feng Y; Yan X
J Hepatol; 2021 Jan; 74(1):245-246. PubMed ID: 33008623
[No Abstract] [Full Text] [Related]
20. Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naïve patients with chronic hepatitis B-related compensated cirrhosis in Taiwan.
Hu TH; Yueh-Hsia Chiu S; Tseng PL; Chen CH; Lu SN; Wang JH; Hung CH; Kee KM; Lin MT; Chang KC; Lin MC; Chien RN
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1695-1706. PubMed ID: 33111400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
